About 45% of teens and adults in the U.S. have some form of fatty liver disease, with Hispanic populations being more affected than other…
News
ALAGILLE SYNDROME
NewsCase study highlights challenges to diagnosis of Alagille syndrome
A diagnosis of Alagille syndrome can be challenging, particularly in areas that lack access to genetic testing and specialized imaging, a case report from…
HEPATITIS
NewsStudy uncovers how hepatitis E can lead to kidney damage
Researchers have identified a possible mechanism by which infection with the hepatitis E virus (HEV), a known cause of liver inflammation, can lead to…
CHOLANGITIS
NewsFDA rejects full approval of Ocaliva as second-line PBC treatment
The U.S. Food and Drug Administration (FDA) has turned down a request by Intercept Pharmaceuticals for the full approval of Ocaliva (obeticholic acid) as…
CHOLESTASIS
NewsHigh urine protein may be common sign of ICP, study finds
About 1 in 3 pregnant women with intrahepatic cholestasis of pregnancy (ICP), the most common pregnancy-related liver complication, had proteinuria, or high levels of…
BILIARY ATRESIA
NewsAmerican Liver Foundation funds 4 research projects in biliary atresia
The American Liver Foundation (ALF) has announced the eight winners of its 2024 Pilot Research Awards, with four of the awards going to scientist-led…
Precision Biosciences has opened a first-in-human trial testing its gene-editing therapy candidate PBGENE-HBV in people with chronic hepatitis B infections, and says data…
CHOLANGITIS
NewsIqirvo to treat PBC approved for public funding in England and Wales
England’s National Institute for Health and Care Excellence (NICE) has recommended that Iqirvo (elafibranor) be covered by the country’s National Health Service (NHS)…
CHOLESTASIS
NewsPFIC caused by USP53 usually mild form of liver disease: Study
Progressive familial intrahepatic cholestasis (PFIC) caused by mutations in the USP53 gene results in a fairly mild form of the disease, with most of…
FATTY LIVER DISEASE
NewsSagimet planning Phase 3 trials of denifanstat in MASH, MASLD
Sagimet Biosciences is planning the launch of two Phase 3 clinical trials to test its oral therapy candidate denifanstat in people with fatty…
Recent Posts
- Getting ahead of concerns about fatty liver disease in children
- Early trial results testing maralixibat for hard-to-treat itching due by year’s end
- My child with Alagille syndrome is going through a ‘picky eater’ phase
- Biliary atresia treatment AX-0810 faring well in early testing
- Clinical trial results support bepirovirsen for hepatitis B